MUSK and myasthenia gravis: In the phase 2, randomized, double-blind, placebo-controlled study, 60 patients with generalized AChR- or MuSK antibody positive MG are planned to be enrolled in 4 active and 1 placebo treatment arms (Table 2) (30).